Alignment Ventures provides seed-stage venture capital for life science startups. We spin companies out of University technology and serve as interim CEOs until sufficient risk reduction tasks are achieved to raise a Series A financing. We are seed artists and life science executives with over 100 years of experience starting, building, financing and exiting from biotech, medical device, health care IT and life science tools companies, both as CEOs and as life science venture capitalists. If it saves lives or reduces morbidity and can make a big difference, we're interested .
We start with a development in science or engineering that solves a critical unmet medical need. We form a newco and serve as an interim management team, with one of us taking the lead as the interim CEO. We invest our own capital and raise non-dilutive funds while managing the many risk reducing tasks that need to be performed to get our seedlings to the point where they can raise a Series A financing. This involves technology licensing, IP strategy, recruitment of an industry-experienced VPR&D, design and execution of risk reducing experiments that establish commercial proof of concept, setting strategy, writing the business plan and financial models, market research, competitor analysis, financing strategy and finally, recruiting the right long-term CEO with decades of operational experience in the appropriate niche. Then we raise the next financing, back out and do it again. We invest up to and including Series A.
We have done this before, over and over. At Norwest Venture Partners, Medical Innovation Partners and here at Alignment Ventures. We have had investments in companies we have run or coinvested in with Avalon, Kleiner, ARCH, Mayfield, Brentwood, Interwest, MDS Health Ventures, Ventures West and Lombard, Odier and Cie, to name a few. This is hard stuff. And you rarely get it right the first time through. Don't go it alone.
Michael founded Alignment Ventures. He has previously been a life science venture capitalist (Norwest Venture Partners, Medical Innovation Partners) as well as a senior executive in a number of life science companies. He was the CEO of TomegaVax, which demonstrated long-term effector memory T-cell responses in primates, until acquisition by Vir Biotechnology (NASDAQ: VIR) in 2016. Michael started his career as a research chemist in the pharmaceutical and diagnostics industry (Syntex and Syva Research). Michael has done strategic alliances with many pharma companies, as well as raising over $500 MM in equity capital, including two IPO’s to date. Michael holds an MBA from the Sloan School of Management at MIT, an MS in Chemistry from the University of Washington as well as a BA in Chemistry from Reed College. Continuing education has included graduate work in Proteomics, Genomics and Immunology.
Prior to joining Alignment Ventures in 2022, Scurry Johnson founded Capital Conceptions Inc., a Dallas based Venture Capital Firm in 1999. where he invested in healthcare-related and physical-science-based companies as well as leverage buyout /growth equity in the medical device, pain and inflammation control pharma sectors. Recently Scurry led our investment in PercAssist. He also led the Series-A and A1 rounds, at CerSci Therapeutics. CerSci Therapeutics was recently acquired by Acadia Pharmaceuticals (Nasdaq: ACAD), a major middle-market pharmaceutical acquisition. Scurry co-founded Neuro Resource Group, Inc. ("NRG") - a Company now titled InterX Technologies - an innovative pain & inflammation control medical device company. Scurry previously held investment banking positions with NCNB and Goldman Sachs and was with McKinsey & Company in San Francisco. Scurry received a B.S. in Industrial Engineering from Stanford University and as well as an MBA from the Sloan School of Management at MIT.
Rachel is currently the CEO of NeuraMedica, Inc., commercializing a system of bioresorbable polymer clips and applier to close the dura of the spine during Neurosurgery and Orthopedic Surgery in a fraction of the time it currently takes. The company's first product received FDA 510(k) clearance in July, 2022 and sales are ramping. Rachel is a career medical device specialist with more than 23 years of biomedical engineering experience and has held biomedical engineering positions at Illumina, Intuitive Surgical, Aurora Bioscience (acq, Vertex), Acumed and Quanum Medical Concepts before becoming the Founding CEO of NeuraMedica. Rachel has extensive experience in orthopedics, neurosurgery, dentistry, bioabsorbable polymers, mechanical design and all phases of product development. Rachel is a Phase II Reviewer for the National Science Foundation for SBIR and STTR grants as well as a grant reviewer for OHSU Biomedical Innovation Program (BIP). She is also an Advisory board member for Portland Women In Science (PDX WIS). Rachel is also a member of the Diné (Navajo) Nation and enjoys mentoring and supporting other female and Native engineers and entrepreneurs. Rachel holds a BS in biomedical engineering from the University of California, San Diego.
Gerardo is a C-Level executive, serial entrepreneur, inventor, and scholar in the medical device industry. Gerardo founded five medical device companies and is a consultant to over 50 medical device companies in the Silicon Valley area. Gerardo is an advisory board member of the Santa Clara University (SCU) Bioengineering, the University of California in San Francisco (UCSF) Catalyst Program, the UCSF Surgical Consortium, and the Simon Fraser University Bioengineering Innovation Blvd. He is also an adjunct professor at the SCU Graduate School of Bioengineering. Currently, Gerardo is PercAssist, co-founder and CEO.
TomegaVax Michael, CEO. Merged with Vir Biotechnology (www.virbio.com), San Francisco, CA 9/16. NASDAQ: VIR now has 11 drugs in the clinic.
NeuraMedica www.neuramedica.us Oregon City, OR. Rachel, CEO. Bioresorbable polymer clips to close the dura of the spine during Neurosurgery and Orthopedic Surgery. FDA approved product, ramping sales.
PercAssist https://percassist-corp.com Santa Clara, CA. Gerardo, CEO. Nedical device to increase ejection fraction in heart failure patients. First in man human data.
OmnEcoil Instruments www.omnecoil.com Portland, OR. Duffy, CEO. Devices to allow the imaging and biopsy of prostate under MRI guidance in one procedure.
3240 Bryan Street, Reno, Nevada 89503, United States
(415) 559-2092 Michael@alignmentventures.com See us in person: * JPM Life Sciences week, San Francisco: January 13-16, 2025 at the Biotech Showcase.
Copyright © 2024 Alignment Ventures, LLC - All Rights Reserved.
Powered by GoDaddy